Status:

COMPLETED

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

Lead Sponsor:

Allergan

Conditions:

Dry Eye Syndromes

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.

Eligibility Criteria

Inclusion

  • Current use of an artificial tear product
  • Visual acuity of at least 20/32 (while wearing glasses, if necessary).

Exclusion

  • Use of contact lenses in the last 3 months, or anticipated use of contact lenses during the study
  • Cataract surgery, laser-assisted in situ keratomileusis \[LASIK\], or photorefractive keratectomy, within the last 6 months
  • Current eye infection or inflammation

Key Trial Info

Start Date :

November 13 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 16 2015

Estimated Enrollment :

188 Patients enrolled

Trial Details

Trial ID

NCT02280473

Start Date

November 13 2014

End Date

March 16 2015

Last Update

April 16 2019

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

North Bay Eye Associates

Petaluma, California, United States, 94954

2

Eric M. White, OD, Inc.

San Diego, California, United States, 92123

3

Eye Center Northeast

Bangor, Maine, United States, 04401

4

Moyes Eye Center, PC

Kansas City, Missouri, United States, 64154

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease | DecenTrialz